AU2017269582B2 - Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid A - Google Patents

Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid A Download PDF

Info

Publication number
AU2017269582B2
AU2017269582B2 AU2017269582A AU2017269582A AU2017269582B2 AU 2017269582 B2 AU2017269582 B2 AU 2017269582B2 AU 2017269582 A AU2017269582 A AU 2017269582A AU 2017269582 A AU2017269582 A AU 2017269582A AU 2017269582 B2 AU2017269582 B2 AU 2017269582B2
Authority
AU
Australia
Prior art keywords
myeloperoxidase
endotoxin
composition
lipopolysaccharide
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017269582A
Other languages
English (en)
Other versions
AU2017269582A1 (en
Inventor
Robert C. Allen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exoxemis Inc
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of AU2017269582A1 publication Critical patent/AU2017269582A1/en
Application granted granted Critical
Publication of AU2017269582B2 publication Critical patent/AU2017269582B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
AU2017269582A 2016-05-27 2017-04-13 Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid A Active AU2017269582B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342382P 2016-05-27 2016-05-27
US62/342,382 2016-05-27
PCT/US2017/027458 WO2017204918A1 (en) 2016-05-27 2017-04-13 Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a

Publications (2)

Publication Number Publication Date
AU2017269582A1 AU2017269582A1 (en) 2018-10-04
AU2017269582B2 true AU2017269582B2 (en) 2023-12-21

Family

ID=60411564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017269582A Active AU2017269582B2 (en) 2016-05-27 2017-04-13 Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid A

Country Status (9)

Country Link
US (1) US11389514B2 (enExample)
EP (1) EP3463431B1 (enExample)
JP (3) JP6713546B2 (enExample)
CN (1) CN109414485B (enExample)
AU (1) AU2017269582B2 (enExample)
CA (1) CA3022426C (enExample)
IL (1) IL262930B2 (enExample)
MX (1) MX392701B (enExample)
WO (1) WO2017204918A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014493A1 (en) * 2018-07-13 2020-01-16 Allen Robert C Haloperoxidase compositions and uses thereof
WO2022103565A1 (en) * 2020-11-13 2022-05-19 Exoxemis, Inc. Myeloperoxidase-containing compositions and uses thereof
WO2024126571A1 (en) * 2022-12-14 2024-06-20 Universite de Bordeaux Artificial bifunctional enzyme comprising a myeloperoxidase activity and a glucose oxidase activity and applications thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US6294168B1 (en) * 1991-02-21 2001-09-25 Exoxemis, Inc. Method for inhibiting pathogenic microbes in an animal using a haloperoxidase-halide-peroxide system
US20090280102A1 (en) * 2008-05-09 2009-11-12 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2108387B (en) 1979-12-28 1984-03-21 Green Cross Corp A pharmaceutical composition containing myeloperoxidase
US5622848A (en) * 1990-05-23 1997-04-22 Medical Discoveries, Inc. Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood
US5565197A (en) * 1991-02-21 1996-10-15 Exoxemis, Inc. Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5888505A (en) * 1991-02-21 1999-03-30 Eoe, Inc. Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system
CA2839747A1 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US6294168B1 (en) * 1991-02-21 2001-09-25 Exoxemis, Inc. Method for inhibiting pathogenic microbes in an animal using a haloperoxidase-halide-peroxide system
US20090280102A1 (en) * 2008-05-09 2009-11-12 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof

Also Published As

Publication number Publication date
MX392701B (es) 2025-03-24
CN109414485B (zh) 2022-08-12
US11389514B2 (en) 2022-07-19
CA3022426C (en) 2023-05-16
WO2017204918A1 (en) 2017-11-30
JP2021181500A (ja) 2021-11-25
JP6713546B2 (ja) 2020-06-24
CN109414485A (zh) 2019-03-01
AU2017269582A1 (en) 2018-10-04
IL262930B1 (en) 2023-07-01
EP3463431B1 (en) 2024-09-18
IL262930B2 (en) 2023-11-01
EP3463431A4 (en) 2020-01-15
CA3022426A1 (en) 2017-11-30
US20190183983A1 (en) 2019-06-20
EP3463431A1 (en) 2019-04-10
JP2020111620A (ja) 2020-07-27
MX2018013925A (es) 2019-03-28
IL262930A (en) 2018-12-31
JP2019515881A (ja) 2019-06-13
EP3463431C0 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
RU2529799C2 (ru) Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения
JP7149858B2 (ja) 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
McKay et al. Broad spectrum aminoglycoside phosphotransferase type III from Enterococcus: overexpression, purification, and substrate specificity
Imamura et al. Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases from Staphylococcus aureus
US20160074446A1 (en) Antibacterial Phage, Phage Peptides And Methods Of Use Thereof
AU2017269582B2 (en) Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid A
Tseng et al. Effects of toluidine blue O (TBO)-photodynamic inactivation on community-associated methicillin-resistant Staphylococcus aureus isolates
Vu-Thien et al. Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidans transmitted by chlorhexidine in a burns unit
Dekigai et al. Mechanism of Helicobacter pylori-associated gastric mucosal injury
EP2533802B1 (en) Methods of reducing or inhibiting toxic effects associated with a bacterial infection using alkaline phosphatase
Brezis Forefronts in nephrology: summary of the newer aspects of renal cell injury
JP2017502093A (ja) 生物活性のヘム−ハロペルオキシダーゼ組成物およびその使用方法
ZA200300013B (en) Antimicrobial agent.
HK40005977B (en) Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a
HK40005977A (en) Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a
JP2021531333A (ja) ハロペルオキシダーゼ組成物およびその使用
BRPI0909447B1 (pt) Composição para inibir o crescimento de microrganismos grampositivos e gram-negativos e uso de uma composição

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)